Fate Therapeutics Inc (FATE)

[jondoeuk]

I can see why they chose the targets they did, but it makes little sense to waste resources as there are a lot of (good) therapies targeting CD19, BCMA and HER2 either approved or in development https://www.modulustherapeutics.com/pipeline

Focusing on MTX-202, Catamaran Bio are already further along with CAT-179. It is off-the-shelf, has an optimised CAR for NKs, dominant-negative TGF-B receptor and IL-15, engineered using a non-viral system https://catamaranbio.com/wp-content/uploads/2022/11/Moore_et_al._SITC_2022-poster_final.pdf

They are also working on a number of switch receptors, including https://catamaranbio.com/wp-content/uploads/2022/05/Storer_et_al._ASGCT_2022.pdf